Drugs / 5-aminosalicylic acid
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00069498 | Oct 1999 → ? | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 3 | NCT02683733 Comparator | Feb 2016 → Feb 2017 | ulcerative colitis | Asian Institute of Gastroenterology, India | Unknown | No outcome recorded |
| Phase 3 | NCT01320436 Comparator | Jul 2011 → Sep 2014 | ulcerative colitis | Sheba Medical Center | Completed | Met primary |
| Phase 3 | NCT00984568 Comparator | Nov 2009 → Mar 2012 | ulcerative colitis | Merck Sharp & Dohme LLC | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 5-aminosalicylic acid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00069498 ↗ |
| Known as | 5ASA | “the effect of the anti-inflammatory drug 5-aminosalicylic acid (5-ASA) on the gut mucosa” NCT00069498 ↗1“5-aminosalicylic compounds (5ASA) such as olsalazine and mesalamine” NCT01320436 ↗ |
| Route | Oral | “5-ASA administered orally at a dose of 2 g/day.” NCT00984568 ↗ |